Description: Olokizumab is a monoclonal antibody which provides a unique mode of action by direct inhibition of IL-6.
Olokizumab is a novel interleukin 6 (IL-6) inhibitor, a humanized monoclonal antibody of Ig G4/ϰ isotype Solution for subcutaneous injection, 160 mg/mL, 0.4 mL vial, shelf life is 3 years, manufactured by R-Pharm JSC (marketing authorization in Russia No. ЛП-006218 dd 21/05/2020). It is the Rx drug that should be administered at the physician's prescription. Before starting olokizumab, please see the Full Prescribing Information t_onReady(function() { t_onFuncLoad('t890_init', function(){t890_init('32208898